These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20307256)

  • 1. Update information on drug metabolism systems--2009, part I.
    Guengerich FP; Rendic S
    Curr Drug Metab; 2010 Jan; 11(1):1-3. PubMed ID: 20307256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.
    Rendic S; Guengerich FP
    Curr Drug Metab; 2010 Jan; 11(1):4-84. PubMed ID: 20302566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Toxicology and pharmacogenetics].
    Dalhoff KP; Poulsen HE
    Ugeskr Laeger; 2005 May; 167(20):2170-2. PubMed ID: 15987076
    [No Abstract]   [Full Text] [Related]  

  • 4. Applications of mass spectrometry in drug metabolism: 50 years of progress.
    Wen B; Zhu M
    Drug Metab Rev; 2015 Feb; 47(1):71-87. PubMed ID: 25639893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC-MS-based metabolomics in drug metabolism.
    Chen C; Gonzalez FJ; Idle JR
    Drug Metab Rev; 2007; 39(2-3):581-97. PubMed ID: 17786640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of mass spectrometry for in-vitro ADME assays.
    Chu I; Nomeir AA
    Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective.
    Tang W; Wang RW; Lu AY
    Curr Drug Metab; 2005 Oct; 6(5):503-17. PubMed ID: 16248842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead optimization strategies as part of a drug metabolism environment.
    Korfmacher WA
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual response to drug therapy: bases and study approaches.
    León-Cachón RB; Ascacio-Martínez JA; Barrera-Saldaña HA
    Rev Invest Clin; 2012; 64(4):364-76. PubMed ID: 23227587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Genetic polymorphism of the hepatic metabolism of drugs].
    Larrey D; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1985; 9(6-7):522-31. PubMed ID: 3926587
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenomics: translating functional genomics into rational therapeutics.
    Evans WE; Relling MV
    Science; 1999 Oct; 286(5439):487-91. PubMed ID: 10521338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical tools and approaches for metabolite identification in early drug discovery.
    Chen Y; Monshouwer M; Fitch WL
    Pharm Res; 2007 Feb; 24(2):248-57. PubMed ID: 17048114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
    Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
    Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.
    Johnson AD; Wang D; Sadee W
    Pharmacol Ther; 2005 Apr; 106(1):19-38. PubMed ID: 15781120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM; Bogaert MG
    Acta Clin Belg; 1996; 51(4):254-60. PubMed ID: 8858891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
    Roberts SA
    Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.